Description
Indication & Scope
Rituximab Injection (Halpryza®) is a chimeric anti-CD20 monoclonal antibody that specifically binds CD20 antigen on mature B lymphocytes, mediating B-cell lysis and depletion, reducing abnormal B cells and treating CD20-positive B-cell malignancies.
- Mechanism
Bind CD20 antigen on B lymphocytes, eliminate abnormal B cells via immune-mediated cell death - Drug class
Anti-tumor Monoclonal Antibody / Anti-CD20 Targeted Therapy - Clinical use
CD20-positive B-cell non-Hodgkin’s lymphoma and chronic lymphocytic leukemia
| Generic Name | Rituximab Injection |
| Brand Name | Halpryza® |
| Ingredient | Rituximab |
| Dosage Form | Injection |
| Package | 10ml:100mg/vial |
| Conditions Treated | Relapsed or chemotherapy-resistant follicular central lymphoma (B-cell non-Hodgkin’s lymphoma);Previously untreated CD20-positive stage III-IV follicular non-Hodgkin’s lymphoma (combined with chemotherapy);Maintenance monotherapy for follicular lymphoma achieving complete/partial remission after initial combination chemotherapy;CD20-positive diffuse large B-cell non-Hodgkin’s lymphoma (combined with CHOP chemotherapy);CD20-positive chronic lymphocytic leukemia (combined with FC chemotherapy) |
| Taboos | Hypersensitivity to rituximab, murine proteins or any excipients of the formulation |
| Place of origin | Jiangsu,China |
| Priscription Type | Prescription drug (Rx) |
| Storage Conditions | Store at 2℃-8℃, protected from light, do not freeze, avoid shaking |
| Manufacturer | Innovent Biologics (Suzhou) Co., Ltd. |
| Registration Authority | National Medical Products Administration (NMPA) |
| Approval number | S20200022 |
| Date of Revision | August 11, 2025 |
| Shelf Life | 24 months |
How to use ?
Recommended Dose: 375mg/m² body surface area, intravenous infusion, regimen varies by disease; premedicate with antipyretic, antihistamine and glucocorticoid to prevent infusion reactions
Time: Slow intravenous infusion; initial infusion over several hours with close monitoring, do not give as rapid IV push
Interaction: Increased risk of severe infection and myelosuppression with chemotherapy/immunosuppressants; monitor for hepatitis B reactivation
Side effects: Infusion-related reactions (fever, chills, hypotension), infections, myelosuppression, hepatitis B reactivation, interstitial lung disease, fatigue
Important Notice
This product shall only be used for post-exposure rabies prophylaxis by professional medical staff. It must be applied combined with rabies vaccine and injected via wound infiltration plus intramuscular routes as specified. Do not administer intravenously or alter the dosage at will. Hypersensitivity monitoring is required throughout the whole injection process.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What key risk needs screening before use?
Hepatitis B virus infection, to prevent fatal hepatitis B reactivation.
What is the main indication of rituximab injection？
CD20-positive B-cell non-Hodgkin’s lymphoma and chronic lymphocytic leukemia.
What type of drug is rituximab?
A chimeric anti-CD20 monoclonal antibody, B-cell targeted anti-tumor biologic drug.
What monitoring is needed after treatment?
Regular blood routine, viral hepatitis screening, and monitoring for infection symptoms.
Halpryza® | Rituximab Injection | Lymphoma | DengYueRX
INN: Rituximab
Indications: Lymphoma
Dosage Form: Injection
Strength: 10ml:100mg/Vial
Original price was: $201.38.$171.17Current price is: $171.17.
